Long-Term Survivors of Breast Cancer: A Growing Population by Bilani, Nadeem et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







Long-Term Survivors of Breast 
Cancer: A Growing Population
Nadeem Bilani, Elizabeth Blessing Elimimian, Leah Elson, 
Hong Liang and Zeina Nahleh
Abstract
Breast cancer represents the most common malignancy among women. 
However, due to effective public health campaigns and updated screening guide-
lines, the annual incidence of late stage diagnoses has fallen. This stage migration 
has allowed for better prognosis and more women achieving long-term survival. 
In this chapter, we review long-term survivorship – defined as 10 years from 
diagnosis – as reported in the United States and around the world. Additionally, 
we provide analysis for socio-demographic, clinical and pathologic factors 
associated with 10-year survival, using data from a large national registry. This 
chapter also utilizes historical case data to forecast stage migration patterns in 
breast cancer diagnoses, within the United States, to 2030. Finally, we discuss the 
effects of the novel coronavirus pandemic on breast cancer treatment and access 
to care, with a review of clinical considerations for the future.
Keywords: breast cancer, epidemiology, survivors, clinical considerations, 
forecasting
1. Introduction
In 2015, the World Health Organization reported that cancer ranked within the 
top four reasons for death, before the age of 70, in 113 of the 172 countries surveyed 
[1]. The impact of cancer on women’s health is incontrovertible. An estimated 2.1 
million individuals around the world were diagnosed with breast cancer in 2018, 
alone [2]. It is the most common malignancy in women, matched only in Sub-
Saharan Africa by cervical cancer, due to an elevated prevalence of tumorigenic 
strains of the human papillomavirus [3].
The breast cancer disease burden is expected to increase, due to a number of 
socioeconomic risk factors, including: aging and growth of the population, nul-
liparity, later maternal age at first pregnancy, the use of exogenous hormones 
(i.e. oral contraceptive pills, hormonal replacement therapy), alcohol intake, and 
obesity [4].
In addition to this rising incidence rate, outcomes in breast cancer are improving 
over time. In the United States, mortality has dropped by 40% between 1989 and 
2017 [5]. This is thought to be due to a combination of a) mass screening cam-
paigns that allow caregivers to diagnose the disease at earlier stages, thus offering 
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better prognoses, and b) the evolution of targeted and increasingly-efficacious 
therapeutics.
The relative indolence of most non-metastatic breast neoplasms, compared 
to other malignancies with more acute courses, makes reports of 5-year overall 
survival less clinically relevant, except in patients who already have limited life 
expectancy. Additionally, certain breast cancers may be associated with a high rate 
of late recurrence. For instance, patients with primary tumors that are estrogen 
receptor (ER)-positive develop distant metastasis in 10–20% of cases, five or more 
years following initial diagnosis [6]. Therefore, there is great utility in surveying 
literature, which reports long-term survival outcomes in patients with breast cancer. 
For the purposes of this chapter, we define “long-term survival” as 10-year overall 
survival (OS).
We start by reporting national data from the United States, and exploring vari-
ous socio-demographic, clinical, and pathologic characteristics significantly associ-
ated with 10-year OS. Next, we perform a literature review of epidemiologic studies 
from the United States, and around the world, to survey for trends in this growing 
population. Finally, we explore numerous clinical considerations in addressing the 
needs of this specific population, with lessons learned from the coronavirus disease 
2019 (COVID-19) pandemic, and implications for future clinical care.
2. Prevalence of long-term survivorship in the United States
On an annual basis, the American Cancer Society (ACS) provides national sur-
vival data on breast cancer cases diagnosed within the United States. With respect 
to long-term survival, the society published that current “relative survival rates” for 
women diagnosed with breast cancer are 85% after 10 years and 80% after 15 years 
[7]. These rates are age- and race-adjusted; supported by the provided definition 
of “relative survival” as the “percentage of patients who will survive their cancer 
for a given period of time after diagnosis…compared to survival among people of 
the same age and race who have not been diagnosed with cancer” [8]. Despite high 
heterogeneity within the breast cancer population, the ACS did not stratify long-
term survival rates by other socio-demographic, clinical, or pathologic characteris-
tics in this publication. In order to add to ACS findings, we explored the impact of 
these factors in more granular detail, using OS as reported by the National Cancer 
Database (NCDB).
The NCDB is a United States-based registry which collects de-identified clinical, 
pathologic, and outcomes data on approximately 70% of all cancer diagnoses in the 
country [9]. Data on patients with breast cancer is uploaded into the NCDB from 
over 1,400 facilities, accredited by the Commission on Cancer and the American 
College of Surgeons. At the time of this publication, survival surveillance for 
patients in this repository included data collected through the year 2016. Therefore, 
in order to ensure adequate time had transpired to capture 10-year OS, we selected 
a cohort of patients diagnosed between 2004 and 2006. Univariate analysis was 
conducted to evaluate for independent factors (e.g., age, race, ethnicity, income, 
insurance status, facility type, co-morbidity index, clinical stage, grade, histology, 
oncotype, and treatment type) exhibiting significant association with 10-year 
survival. Subsequently, variables significant at the univariate level were selected 
for inclusion within one multiple logistic regression model also predicting 10-year 
survival. A p-value of <0.001 was considered significant, due to the very large 
sample size that may overpower correlative testing. A total of n = 515,610 patients 
with breast cancer were analyzed in this model. The results are depicted in Table 1, 

















Variable No. (%) 10-year OS
% OR 95% CI p-value
Age <.001
<50 (ref) 125,657 (24.4%) 54.1% 1.000 — — —
50–70 256,003 (49.7%) 53.0% .946 .916 .978 .001
>70 133,950 (26.0%) 30.1% .427 .407 .448 <.001
Race <.001
White (ref) 440,048 (87.6%) 48.0% 1.000 — — —
Black 52,220 (10.4%) 40.7% .821 .786 .858 <.001
Asian 9872 (2.0%) 51.9% 1.166 1.067 1.275 .001
Ethnicity
Hispanic (ref) 445,220 (95.6%) 47.7% 1.000 — — —
Non-Hispanic 20,481 (4.4%) 44.4% .936 .878 .998 .042
Income <.001
<$30,000 (ref) 55,038 (11.0%) 41.8% 1.000 — — —
$30,000–$34,999 79,054 (15.8%) 44.9% 1.026 .977 1.078 .296
$35,000–$45,999 133,171 (26.6%) 46.7% 1.065 1.017 1.115 .008
>$46,000 233,078 (46.6%) 50.5% 1.126 1.076 1.178 <.001
Insurance status <.001
Uninsured (ref) 10,440 (2.1%) 36.8% 1.000 — — —
Private insurance 284,063 (56.5%) 55.4% 1.552 1.417 1.701 <.001
Medicare 181,088 (36.0%) 36.5% 1.264 1.150 1.390 <.001







Variable No. (%) 10-year OS
% OR 95% CI p-value
Facility type <.001
Community cancer program (ref) 46,176 (9.4%) 43.8% 1.000 — — —
Comprehensive community cancer program 227,815 (46.5%) 47.7% 1.125 1.077 1.175 <.001
Academic/research program 142,123 (29.0%) 49.0% 1.063 1.015 1.113 .010
Integrated network cancer program 73,703 (15.0%) 44.6% .819 .776 .865 <.001
Setting .001
Metro (ref) 427,832 (85.6%) 47.6% 1.000 — — —
Urban 63,288 (12.7%) 47.4% 1.076 1.034 1.120 <.001
Rural 8534 (1.7%) 47.4% 1.091 .984 1.209 .099
Charlson/Deyo comorbidity index .000
0 (ref) 450,329 (87.3%) 49.1% 1.000 — — —
1 52,983 (10.3%) 38.3% .746 .717 .777 <.001
2 9425 (1.8%) 25.1% .506 .459 .557 <.001
3 2873 (0.6%) 16.4% .343 .280 .421 <.001
AJCC clinical staging <.001
0 (ref) 59,736 (25.7%) 54.5% 1.000 — — —
1 87,698 (37.7%) 50.0% .731 .703 .760 <.001
2 51,604 (22.2%) 42.4% .526 .503 .551 <.001
3 18,871 (8.1%) 29.7% .281 .264 .299 <.001


















Variable No. (%) 10-year OS
% OR 95% CI p-value
Well-differentiated (ref) 94,046 (21.2%) 51.6% 1.000 — — —
Moderately-differentiated 184,976 (41.7%) 48.5% .889 .860 .919 <.001
Poorly differentiated 164,490 (37.1%) 44.9% .782 .752 .812 <.001
Histology .007
Ductal carcinoma (ref) 367,409 (72.7%) 47.7% 1.000 — — —
Lobular carcinoma 79,387 (15.7%) 47.3% .993 .957 1.031 .720
Other carcinoma 47,959 (9.5%) 49.1% 1.013 .966 1.061 .598
Epithelial-myoepithelial 1861 (0.4%) 42.1% .898 .703 1.146 .385
Papillary 6005 (1.2%) 30.8% 1.054 .883 1.260 .559
Fibroepithelial 2058 (0.4%) 34.9% .937 .755 1.162 .552
Mesenchymal 402 (0.1%) 21.4% .713 0.309 1.645 427
Estrogen receptor status
Negative (ref) 97,628 (21.9%) 43.9% 1.000 — — —
Positive 348,611 (78.1%) 48.6% .908 .868 .949 <.001
Progesterone receptor status
Negative (ref) 147,951 (33.6%) 44.0% 1.000 — — —
Positive 292,529 (66.4%) 49.3% 1.095 1.057 1.134 <.001
Type of surgery .000
None (ref) 30,799 (6.0%) 15.8% 1.000 — — —
Lumpectomy 294,554 (57.3%) 52.6% 2.300 2.112 2.506 <.001








Variable No. (%) 10-year OS
% OR 95% CI p-value
No (ref) 239,355 (47.5%) 40.4% 1.000 — — —
Yes 264,681 (52.5%) 53.3% 1.385 1.341 1.430 <.001
Chemotherapy
No (ref) 309,000 (62.9%) 46.0% 1.000 — — —
Yes 182,510 (37.1%) 49.2% 1.375 1.331 1.420 <.001
Hormonal therapy
No (ref) 245,859 (51.0%) 42.3% 1.000 — — —
Yes 236,454 (49.0%) 51.9% 1.207 1.167 1.248 <.001
HER2-targeted therapy
No (ref) 497,793 (99.6%) 47.2% 1.000 — — —
Yes 1862 (0.4%) 43.3% 1.273 1.236 1.311 <.001
Table 1. 
Multiple logistic regression model for predictors of long-term overall survival in breast cancer in the United States, using data from the National Cancer Database (NCDB).
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2.1 Overall survival by socio-demographic characteristics
Age at diagnosis was significantly associated with likelihood of long-term 
OS. The age distribution of our cohort was: n = 125,657 (24.4%) <50 years old, 
n = 256,003 (49.7%) between 50–70 years old, and n = 133,950 (26.0%) older 
than 70. Long-term OS rates were similar in patients diagnosed before 50 (54.1%) 
compared to those diagnosed between 50 and 70 years of age (53.0%). This may 
highlight the relative indolence of breast cancer as a primary malignancy, particu-
larly when diagnosed and treated at early stages. However, a large drop in 10-year 
OS was seen in those diagnosed after 70 (30.1%), a cohort more likely to experi-
ence acute events due to the cumulative effect of chronic comorbidities such as 
hypertension, diabetes, and dyslipidemia. This is supported by the life expectancy 
of individuals in the United States which, in 2016, was estimated to be 78.9 years 
[10]. The distribution of survival, by age, may differ in other parts of the world, 
particularly in low- and middle-income countries, or those without mass screen-
ing programs.
Racial disparities continue to be a significant major healthcare challenge. In the 
1980s, a marked divergence in death rates between White and Black women with 
breast cancer was first noted [11]. The implementation of mass screening programs 
disproportionately benefited areas wherein residents had access to favorably-resourced 
and accredited healthcare institutions [12, 13]; these communities were predominantly 
White. Additionally, hormonal therapy (e.g. tamoxifen), newly introduced to systemic 
treatment regimens for treatment of ER+ tumors, was not appropriate for many Black 
women, who are more likely to present with triple negative breast cancer (TNBC) – a 
type of breast cancer without ER, PR, or HER2 expression, which is unresponsive to 
tamoxifen regimens [14]. This is elaborated upon in Section 2.2.
Race-based survival disparity peaked in 2011, with mortality rates reported to 
be approximately 45% higher in Black versus White patients with breast cancer 
[5]. Despite improvements over the last decade, race continues to be an important 
predictor of 10-year OS (p < 0.001), as depicted in Figure 1. In our analysis, using 
data extrapolated from the NCDB, patients of Asian descent exhibited the high-
est long-term overall survival rate (51.9%), followed by White (48.0%) and then 
Black (40.7%) patients. Beyond access to healthcare, these race-based disparities 
are thought to be due to the complex interplay between multiple lifestyle factors 
(such as alcohol consumption and smoking), extent of comorbidity (including 
obesity, which is associated with worse outcomes in breast cancer due to increased 
estrogens and inflammatory mediators [15]), and genetics. Interestingly, from our 
analysis, ethnicity (defined in the NCDB as Hispanic vs. Non-Hispanic) was not 
determined to be a significant predictor of 10-year OS, even when adjusting for 
Figure 1. 




relevant confounders such as age, race, comorbidity (Charlson/Deyo index), and 
AJCC clinical stage at diagnosis.
Measures of socioeconomic status – including annual income, insurance 
status, and treatment facility type – were also significantly associated with 
10-year OS in this cohort (p < 0.001). Patients who were uninsured exhibited the 
lowest 10-year OS rates (36.8%), in contrast to patients who had private insurance 
(56.5%), as depicted in Figure 1. A study by Ko, et al., indicates that roughly half 
of all racial/ethnic disparity, associated with the risk of locally-advanced disease, 
can be attributed to insurance status as “uninsured” or “underinsured” [16]. 
Patients without healthcare coverage are less likely to effectively manage chronic 
comorbidities, including hypertension [17] and diabetes [18], which is likely a 
contributing factor of higher mortality observed in this subgroup. While setting 
(urban vs. rural) was not a significant predictor of long-term survival, facility 
type was (p < 0.001), with patients treated at academic cancer programs exhibit-
ing the highest 10-year OS rate (49.0%), followed by those treated at compre-
hensive community cancer programs (47.7%) and those treated at community 
cancer programs (43.8%). This may be due to differences in time-to-diagnosis and 
time-to-treatment, determined by institution size, and care practices that may 
differ based on the accreditation of different cancer programs, as available to 
different communities [19].
2.2 Overall survival by clinical characteristics
As expected, the most important predictor of survival in breast cancer in 
our analysis was ‘stage’ at diagnosis, as depicted in Figure 1. Breast cancer stage 
represents the extent of spread of cancer in the body, expressed on a spectrum 
ranging from 0 (the earliest form, wherein cancer cells are restricted to the milk 
ducts of the breast, but have not invaded other breast tissue) to IV (the latest 
form, where the cancer has spread to another organ in the body, referred to as 
“metastatic”). Staging may be clinical (based on physical exam and imaging 
such as mammogram, ultrasound, or magnetic resonance imaging) or patho-
logic (based on evaluation of breast tissue and lymph nodes removed during 
surgery). We found that the widest disparity in long-term OS was associated 
with clinical stage of diagnosis (54.5% with stage 0, versus just 6.1% with stage 
IV disease, p < 0.001). As the majority of patients in the United States are 
diagnosed at early stages of disease (i.e. 0-II), this supports the positive, clini-
cal impact of public health campaigns that target awareness of prevalence, risk 
factors, signs and symptoms of breast cancer.
Diagnosis of breast cancer is typically confirmed with a biopsy, during which 
a tumor tissue sample is sent for evaluation by specialists in pathology. Through 
microscopy, and the use of staining techniques, numerous pathophysiological 
characteristics of the neoplasm can be determined. Important among them, is the 
‘breast cancer subtype’, referring to the molecular profile of the tumor, based on the 
expression of three receptors on the surface of breast cancer cells: 1) the estrogen 
receptor (ER), 2) progesterone receptor (PR), and the 3) human epidermal fac-
tor growth factor 2 (HER2) receptor. The combination of these receptors forms 
the basis for clinical decision-making regarding targeted therapy in breast cancer. 
For instance, if the primary tumor is ER+/PR+, ‘endocrine’ or ‘hormonal’ therapy 
can be administered (e.g. selective estrogen receptor modulators, or SERMs, like 
tamoxifen, that directly modulate these hormonal receptors, or aromatase inhibi-
tors, which decrease the natural conversion of androgens to estrogens in the body); 
if the tumor exhibits HER2+ status, the monoclonal antibody trastuzumab is given 
to block this receptor subtype.
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The NCDB did not routinely document HER2 receptor status in cases diagnosed 
before 2009, thus the impact of this receptor expression on 10-year OS could not be 
evaluated in this multivariate model. However, the analysis did include ER status 
and PR status, demonstrating that positivity of either receptor significantly pre-
dicted long-term survival. This finding underscores progress made in the improve-
ment of patient outcomes as treatment modalities become more targeted (prior to 
endocrine therapy, non-targeted chemotherapy was the gold standard for treatment 
of even hormone receptor positive breast cancer). This is also strongly reflected 
in one of our previous analyses, indicating that patients with tumors which were 
negative for all three receptors (TNBC), exhibited the lowest rate of 5-year OS 
(71%), followed by the ER-, PR-, HER2+ subtype (77%), the ER/PR+, HER2+ 
subtype (83%), and a highest 5-year OS rate seen in the ER/PR+, HER2- subtype 
(84%) [20].
Interestingly, HER2 overexpression, occurring in around 20% of breast cancers, 
is associated with worse natural prognosis due to increased growth and marked 
metastatic potential of these tumors [21]. However, we have shown that survival 
outcomes in ER/PR-, HER2+ breast cancer, in the United States, have surpassed 
TNBC due to the advent of HER2-targeted regimens. Therefore, HER2+ status may 
be predictive of treatment efficacy in breast cancer. This may not be the case glob-
ally, particularly in low- and middle-income countries which may exhibit limitation 
in drug funding. In 2012, the Union for International Cancer Control and the Dana-
Farber Cancer Institute filed an application with the World Health Organization to 
add trastuzumab (a HER2-targeted therapy) to the essential medications list [22], 
an advisory list of the minimum medicine needs for basic healthcare systems. This 
was not approved until May 2015 [23]. Current literature still reports trans-national 
disparities in the availability of HER2-targeted therapeutics, and advocates for the 
distribution of more affordable trastuzumab biosimilars in order to address this 
ongoing need [24, 25].
Pathologists will also assign a ‘grade’ to the tumor under evaluation using a 
method of classification known as the Nottingham modification of the Scarff-
Bloom-Richardson system [26]. Grading in breast cancer designates how “abnor-
mal” neoplastic cells appear, and is based on the extent of glandular/tubular 
differentiation, nuclear pleomorphism, and mitotic count [27]. Grade 1 tumors are 
“well differentiated”, meaning their growth is slower and appears most similarly 
to normal breast tissue. Grade 3 tumors, on the other hand, are “poorly differenti-
ated”, appearing “dysplastic” (very different from normal cells) and have a higher 
growth potential. Grade 2, tumors have “moderate” differentiation, and fall 
between Grade 1 and Grade 3 in prognostic implication. While not predictive of 
the same breadth of overall survivorship as tumor staging, we found in our NCDB 
analysis that tumor grade was still a statistically significant predictor of 10-year 
OS: patients with Grade 1 tumors exhibited a 10-year OS rate of 51.6% (unadjusted 
for stage at diagnosis) versus those with Grade 2 tumors (48.5%) and those with 
Grade 3 tumors (44.9%). Finally, we also showed that while ‘histological subtype’ 
(referring to the tissue type a neoplasm originated from) was not a statistically-
significant predictor of long-term overall survival (p > 0.001), the highest 10-year 
OS rates were seen in the most common subtypes: ductal carcinoma (47.7%, not 
adjusted for stage at diagnosis) and lobular carcinoma (47.3%). Patients with 
some rare histologies exhibited lower rates of 10-year OS, including epithelial-
myoepithelial (42.1%), fibroepithelial (34.9%), papillary (30.8%), and mesenchy-
mal (21.4%) breast cancers. The scarcity of these subtypes has limited the ability 
to study these unique histologies in a high-throughput manner. However, recent 
studies suggest that tumor histology should be considered when determining the 
optimal treatment approach for each patient [28–30].
Global Women’s Health
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3. Prevalence of long-term survivorship globally
Survival rates for breast cancer vary considerably in different parts of the world. 
The 5-year OS rate – which is more commonly reported and can thus be compared 
when controlling for confounders such as race, stage at diagnosis, age at diagnosis, 
etc. – varies from over 80% in developed countries, to less than 60% in low- and 
middle-income countries [31]. However, less is known about 10-year OS in low- and 
middle-income countries. We conducted a systematic search using MEDLINE, via 
PubMed and Google Scholar, from inception until December 2020. We included 
observational cohort studies also reporting OS rates if published in the English 
language. The search strategy involved a combination of free text searches, as well 
as medical subject headings (MeSH), as follows: (“Breast Neoplasms” [MeSH], 
OR “breast cancer” OR “breast tumor”) AND (“Survival” [MeSH] OR “Survival 
Rate” [MeSH] OR “Life Tables” [MeSH] OR “Kaplan–Meier Estimate” [MeSH] 
OR “Hazard Ratio” OR “Cox regression”) AND (“Cohort Studies” [MeSH] OR 
“Retrospective Studies” [MeSH] or “Prospective Studies” [MeSH] OR “follow-up” 
or “longitude”).
We found n = 37 studies reporting 10-year OS rates, as presented in Table 2. 
The majority were from high income countries (n = 27, 73%), while n = 10 (27%) 
reported data from low- and middle-income countries. It was found that high 
income countries have been reporting long-term OS data over a longer period of 
time (1978–2020), while data from low- and middle-income countries have been 
published more recently (2008–2020). Additionally, cohorts used in studies from 
high income countries were larger (mean sample size: n = 1,573) than those from 
low- and middle-income countries (mean sample size: n = 268). In comparing 
data published since the year 2000, the mean 10-year OS rate from high-income 
country studies was 72%, versus the mean 10-year OS rate from low- and middle-
income countries studies, which was 64%. However, these comparisons do not 
control for the impact of patients age at diagnosis (most studies did not report a 








Low- and middle-income countries
Mai TTX et al. 2019 Korea 206 47 +/− 9 0.88
Dolatkhah R et al 2019 Iran 4989 50.4 
+/− 13
0.65
Bender MPF et al 2015 Brazil 264 63 +/− 13 0.41
Ziaei JE et al 2013 Iran 271 48 0.76
Li BJ et al 2012 China 84 57 +/− 11 0.63
Gokce T et al 2011 Turkey 1746 51 0.79
Xia LP et al 2010 China 70 NR 0.73
Heydari ST et al 2009 Iran 877 47 +/− 12 0.46
Rajaeefard AR et al 2009 Iran 310 NR 0.53
Yaghmaei et al 2008 Iran 50 52 +/− 14 0.47
High-income countries
Wu SC et al 2020 Taiwan 2,002 NR 0.78
Ameijide A et al 2019 Spain 10,195 NR 0.41
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mean age), disease stage at diagnosis (though all cohorts reported individuals from 
all four stages of breast cancer), race, or the presence of comorbidities in these 
cohorts. Therefore, more information will be needed to calculate pooled estimates 
of global survival, by region or country. This review of studies reveals a stark 
disparity in the availability of long-term outcomes data from different regions 
around the world.
4. Forecasting stage of diagnosis in the United States to 2030
As mentioned, the strongest predictor of 10-year survival outcomes, in breast 
cancer, is stage at diagnosis. As diagnostic capabilities continue to facilitate earlier 
identification of disease, it is important to understand how stage migration is 








Ignatov A et al 2018 Germany 12,053 NR 0.82
Yoshimura A et al 2018 Japan 63,348 NR 0.79
Park EH et al 2017 Korea 109,988 NR 0.85
Plichta JK et al 2016 USA 584 NR 0.86
Campbell ID et al 2015 New 
Zealand
101,824 NR 0.84
Fong Y et al 2014 England 1,712 NR 0.77
Hamadeh RR et al 2014 Bahrain 1,005 51 0.49
Hauth EA et al 2012 Germany 222 NR 0.96
Marchal F et al 2009 France 116 66 +/− 12 0.52
Thalib L et al 2009 Sweden 300,011 NR 0.64
Ueno M et al 2007 Japan 559 NR 0.75
Jayasinghe UW et al 2005 Australia 393 54 0.69
Tejler G et al 2004 Sweden 7,892 NR 0.54
Minelli L et al 2004 Italy 2,460 NR 0.47
Jensen AR et al 2003 Denmark 1,573 56 0.66
Twelves CJ et al 2001 Scotland 1,617 NR 0.52
Barchielli A et al 1999 Italy 1,182 NR 0.53
Fakhro AE et al 1999 Bahrain 93 50 0.36
Wallgren A et al 1997 Sweden 75 NR 0.54
Sariego J et al 1995 USA 81 NR 0.49
Sant M et al 1991 Italy 1,991 NR 0.5
Toikkanen S et al 1990 Finland 461 NR 0.37
Isard HJ et al. 1988 USA 70 57 0.7
Adami HO et al 1985 Sweden 12,319 NR 0.38
Heller KS et al 1978 USA 304 65 0.62
Table 2. 
Review of global cohort data reporting long-term overall survival rates of breast cancer.
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predicted to change in the future – an important metric for allocation of resources 
and services needed for this growing group of survivors.
In order to understand future stage migration patterns, in a cohort of long-term 
survivors of breast cancer, there is utility in forecasting the predicted proportion of 
cases that are expected to be early stage (0, I or II) versus late stage (III or IV) based 
on historical trends. To do this, we extracted annual incidence data from the NCDB 
from 2004–2016, stratifying by cases that were diagnosed at early stage versus 
those at late stages. This data was analyzed via time-series forecasting, specifically 
autoregressive integrated moving averages (ARIMA) modeling, which considers 
annual variation and accounts for temporal correlation in analysis of historical data 
[32]. The performance of ARIMA models has been found to be comparable to other 
time series models in its capacity to forecast healthcare data, such as the Bayesian 
shared two-component model [33].
Multiple ARIMA models were generated using the Statistical Package for the 
Social Sciences (SPSS) Version 27.0 software (IBM Corp, Armonk, NY) using 
different combinations of the autoregressive parameters for ‘p’, the order of 
the autoregressive model, ‘d’, the degree of differencing and ‘q’, the order of the 
moving average (p, d, q). The most predictive model was selected using the lowest 
Bayesian Information Criteria, and mean absolute percentage error, and this was 
the (0, 1, 0) ARIMA model. Figure 2 depicts 1) the historical incidence of breast 
cancer in the United States (black curve), stratified by stage at diagnosis (blue 
for early-stage and red for late-stage) for the years 2004–2016, and 2) forecasted 
incidence of total, early stage and late stage cases to the year 2030. The annual 
proportion of new cases diagnosed at late-stage is highlighted on as an embold-
ened numerical figure in red. Tabulated numerical data of these forecasts can be 
found in Table 3.
We found that, based on historical trends, the proportion of cases diagnosed at 
advanced stages of disease is projected to fall to 10.7%, compared to the historical 
proportion, in 2004, of 19.8%. Based on this projected stage migration, we can 
expect the number of long-term survivors in the United States to continue to grow. 
In Section 5, we discuss the impact of the COVID-19 pandemic on mass screening, 
and implications for staging and care of patients diagnosed during 2020.
Figure 2. 

















Year Total Incidence Incidence Diagnosed at Early Stages 
(0–2)
Incidence Diagnosed at Late 
Stages [3–4]
% of Cases Diagnosed at 
Advanced Stages
Historical data from the 
NCDB
2004 53,551 42,970 10,581 19.76%
2005 57,902 46,792 11,110 19.19%
2006 62,412 50,503 11,909 19.08%
2007 75,251 61,786 13,465 17.89%
2008 114,666 97,699 16,967 14.80%
2009 132,520 114,357 18,163 13.71%
2010 141,328 121,716 19,612 13.88%
2011 151,081 130,967 20,114 13.31%
2012 156,102 135,506 20,596 13.19%
2013 164,902 143,840 21,062 12.77%
2014 171,275 149,422 21,853 12.76%
2015 177,569 155,709 21,860 12.31%







Year Total Incidence Incidence Diagnosed at Early Stages 
(0–2)
Incidence Diagnosed at Late 
Stages [3–4]
% of Cases Diagnosed at 
Advanced Stages
Forecasted data using 
(0,1,0) ARIMA modeling
2017 185,438 163,170 22,268 12.01%
2018 195,583 172,416 23,167 11.85%
2019 205,728 181,662 24,066 11.70%
2020 215,873 190,908 24,965 11.56%
2021 226,018 200,154 25,864 11.44%
2022 236,164 209,401 26,763 11.33%
2023 246,309 218,647 27,662 11.23%
2024 256,454 227,893 28,561 11.14%
2025 266,599 237,139 29,460 11.05%
2026 276,744 246,385 30,359 10.97%
2027 286,889 255,631 31,258 10.90%
2028 297,035 264,878 32,157 10.83%
2029 307,180 274,124 33,056 10.76%
2030 317,325 283,370 33,955 10.70%
Table 3. 
Historical incidence and forecasted incidence to 2030 of breast cancer in the United States, using data from the National Cancer Database (NCDB).
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5. Impact of the COVID-19 pandemic
5.1 COVID-19: Epidemiology & healthcare impacts
The COVID-19 pandemic is now a defining feature of the year 2020. This novel 
coronavirus was identified in 2019, as the etiology of a pneumonia diagnosis in 
Wuhan, in the Hubei province in China [34]. Genomic sequencing and phyloge-
netic analysis indicated that the coronavirus that causes COVID-19 is of the same 
subgenus as the severe acute respiratory syndrome (SARS) virus [35, 36]. This led 
to the determination that COVID-19 is due to severe acute respiratory syndrome 
coronarivurs-2. Following its discovery, the outbreak of this disease spread rapidly: 
on January 10, 2020, the genomic sequence of SARS-CoV-2 was released and shared 
globally by China [37]; by February of 2020, COVID-19 had quickly spread through 
the Hubei province [38]; and On March 11,2020, the World Health Organization, 
had declared the COVID-19 outbreak a global emergency and pandemic [38].
In an attempt to flatten the epidemiologic growth curve of new COVID-19 
diagnoses, public health departments implemented targeted social measures to 
decrease transmission rates. This included emphasis on social distancing, stay-at-
home mandates, a requirement of face masks worn in public, and hand hygiene 
[39]. Additionally, in order to reduce mortality and relieve the case-load pressure 
on clinical care providers, many healthcare systems were forced to change clinical 
practice. While there has been much investigation into the pathology and biologic 
effects of COVID-19, the overall impact of COVID-19 on management of chronic 
health outcomes – including breast cancer management and overall survival – is still 
evolving.
Due to the COVID-19 pandemic, the mechanism for healthcare delivery has 
changed substantially. One of the changes seen in the United States, was the broad 
adoption of telemedicine and the upheaval of the in-person visit. Prior to the year 
2020, the use of telemedicine was unsubstantial [40]. However, telemedicine visits 
increased from 1.1% during the second quarter (Q2) of 2019, to 35.3% in Q2 of 2020 
[41]. Correspondingly, as the rise in the rate of remote visits increased, the number 
of in-person visits decreased – the number of office-based health care visits in Q2 of 
2020, decreased by 50.2% compared with the previous year [41]. While helping to 
slow the dissemination of COVID-19, this decrease of in-person visits has made the 
full-spectrum of care for patients with breast cancer challenging, because physi-
cal exams and in-person evaluations have also declined. As a result, co-morbidity 
management may have also suffered: during Q2 of 2020, blood pressure assessments 
decreased by 50.1%, while cholesterol assessments decreased by 35.3% [41].
The overall effect of COVID-19 on delays in cancer diagnosis, disruptions in 
treatment, and modifications to therapeutic regimens is still being evaluated. One 
report, including 609 patients with breast cancer, identified treatment delays for 
44% of the study population, aged 45 years and younger [42]. Another study sug-
gests a higher death rate in cancer patients in receipt of recent therapy, however the 
proportion of patients reported on active therapy, in this study, was marginal and 
thus conclusive correlation cannot be determined [43–45]. Literature has shown 
that patients with cancer, when compared to those without cancer, are at increased 
susceptibility to infection, secondary to systemic immunosuppression from their 
cancer or anticancer therapy [46–49]. Initial reports suggested patients with cancer 
experienced more frequent COVID-19 complications [43, 50, 51]. As a result, 
physicians and patients must strategically balance the risks of cancer advancement, 
cancer relapse, etc. with the risks of hospitalization or death secondary to a COVID-
19-related complication. Through diagnoses to management, special concern for 
patients with cancer is warranted due to the pandemic.
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Patients with breast cancer might be at an increased risk for treatment-related 
complications and other health issues during the COVID-19 pandemic. The CDC 
reports that having cancer increases your risk of severe illness from COVID-19 [52]. 
Several studies have been conducted with respect to the effects of COVID-19 on 
patients with cancer. One multicenter study was conducted to evaluate the clinical 
characteristics of COVID-19-infected patients who died within 28 days of hospital-
ization in the intensive care unit [53]. This study reported 784 deaths after 28 days, 
60 of these deaths (7.7%) were among those with active cancer; their multivariable 
model revealed that active cancer was associated with increased COVID-19-driven 
mortality (odds ratio (OR), 2.15; 95% CI, 1.35–3.43) [53]. An additional multi-insti-
tutional study was performed to evaluate the impact of COVID-19 on patients with 
active or prior malignancies [54]. The primary end point of this analysis was all-
cause mortality, within 30 days of a COVID-19 diagnosis. Within this population, 
22% had hematologic malignancies, and the remainder were previously diagnosed 
with solid tumors [54]. This study did not find an association between increased 
COVID-19-related mortality and cancer type, anticancer therapy, or recent sur-
gery. There were several factors associated with increased 30-day mortality: male 
sex (OR, 1.63 [95% CI, 1.07–2.48]), older age (per 10 years) (partially adjusted 
OR, 1.84 [95% CI, 1.53–2.21]), increased comorbidities (≥2) (OR, 4.50 [95% CI, 
1.33–15.28]), a previous smoking status (OR, 1.60 [95% CI, 1.03–2.47]), Eastern 
Cooperative Oncology Group performance status 2 (OR, 3.89 [95% CI, 2.11–7.18]) 
or more (OR, 5.66 [95% CI, 2.79–11.47]), and progressive cancer (defined as no 
longer responding to treatment) (OR, 5.20 [95% CI, 2.77–9.77]) [54].
5.2 Relationship between COVID-19 and breast cancer
The increased risk of severe illness, secondary to COVID-19, in patients with 
breast cancer [52] might be multifaceted. Both cancer, and cancer treatment, can 
cause a significant physiologic strain on protective mechanisms of the human 
body. The immune system is intrinsically linked to breast cancer pathogenesis 
via inflammatory pathways, immune surveillance, and adaptive immunity [55]. 
Chronic inflammatory activity has been discovered in all breast cancers, regard-
less of breast cancer subtype [56]. This chronic inflammation can lead to damaged 
breast cells, which may support continued tumor progression, with some breast 
cancer models revealing CD4+ T lymphocytes indirectly promoting invasion and 
metastasis [57].
An additional reason for a potentially increased risk of serious complications, 
including death, secondary to COVID-19, in breast cancer patients, is impaired 
immunity due to chemotherapy. Treatment, with chemotherapy or radiation 
therapy, can lead to chronic pain, immune suppression, treatment-related toxicities, 
failure to thrive, and decreased physical and cognitive abilities [58]. Chemotherapy 
has been shown to induce neutropenia and lymphopenia in patients [59]. Women 
with breast cancer, who were treated with adjuvant therapy that consisted of 
chlorambucil, methotrexate, and 5-fluorouracil had decreased peripheral blood 
lymphocytes [60]. Similarly, other studies report decreased CD4+ cell counts along 
with concurrent pneumocystis pneumonia in patients with breast cancer who had 
received multi-agent chemotherapy and radiation therapy [61].
The relationship between the uses of immune check point inhibitors (ICIs) in 
breast cancer patients is another new area of interest during the COVID-19 pan-
demic. Several ICIs have been developed targeting breast cancer; some of the most 
clinically-advanced are those that target programmed cell death-1 (PD-1) and pro-
grammed cell death ligand-1 (PD-L1) [62]. Anti-PD-1/PD-L1 agents are an emerg-
ing treatment modality with encouraging results for aggressive breast tumors, like 
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triple negative breast cancers [63]. These ICI therapies, however, are associated with 
several significant side effects -- one of which includes inflammatory syndromes 
like pneumonitis, which targets the lungs [64, 65]. These treatments have also been 
associated with increased inflammation and tissue damage [66, 67]. Currently, 
reports evaluating the relationship between anti-PD-1/PD-L1 agents and COVID-19 
are ongoing. But, some preclinical studies reveal that viral clearance is accelerated 
by PD-1/PDL-1 pathways and, thus blocked by immune check point inhibitors [68]. 
Other reports have associated COVD-19 with increased T-cell exhaustion when 
there is increased expression of PD-1 and PDL-1 [69].
As the effect of COVID-19 on breast cancer patients in receipt of ICIs is still 
being evaluated, members of the medical community defer to historical trends 
between ICIs and other viruses for clinical decision making. For instance, the 
checkpoint inhibitor, pembrolizumab has demonstrated efficacy in a subset of 
patients with progressive multifocal leukoencephalopathy caused by JC virus 
infection [70]. Additionally, some studies have noted that ICIs exacerbate viral lung 
infections, with increased toxicities observed in the winter months when the major-
ity of the population are diagnosed with colds and the flu [71, 72].
Although there are increased risks and side effects associated with the use of 
chemotherapy and ICIs during the COVID-19 pandemic, the benefits of these 
treatment modalities could outweigh the risks. The OS of breast cancer patients 
has improved significantly over the last three decades, due in part to improvements 
in systemic chemotherapy, endocrine therapy, targeted therapy, and recently the 
application of ICIs [73, 74]. Therefore, while breast cancer therapies may be associ-
ated with negative side effects, recovery is possible with appropriate management, 
dependent upon tumor burden and the overall health status of the patient [75–77]. 
In order to maximize the clinical efficacy of these treatment modalities, while limit-
ing COVID-19-related health risks, additional research is needed to guide practice.
6. Clinical considerations of a growing cohort of long-term survivors
While outcomes following treatment of invasive breast cancer have become 
increasingly favorable, survivors remain at-risk for recurrence of disease, either 
loco-regionally or at a distant site. In one large cohort of 9,514 women diagnosed 
with breast cancer under the age of 75, 10.4% developed distant metastasis, most 
commonly at a bony site [78]. Patients were more likely to experience recurrence in 
the period 5–10 years after diagnosis, if they presented with primary tumors that 
were ER-positive, lymph-node positive, or larger than 20 mm in size [78]. Women 
with ER-negative tumors, however, have a lower risk during this period. The devel-
opment of multigene sequencing panels predicting outcomes in ER-positive tumors 
can guide clinicians to ensure at-risk patients receive the appropriate adjuvant 
therapy.
Survivors of breast cancer should undergo regular follow-up for surveillance 
and management of treatment-related effects, as well as breast-specific and other 
indicated imaging to evaluate for malignant recurrence, or new disease. This man-
agement necessarily includes a wide range of disciplines in medicine. Breast surgery 
or radiation therapy can result in chronic pain, fibrosis, fat necrosis, or recurrent 
skin infections in the chest wall [79, 80]. Patients are also at long-term-risk for 
cardiovascular dysfunction, including congestive heart failure [81], ovarian failure 
[82], and even the development of secondary cancers [83]. For this reason, the care 
of long-term survivors of breast cancer should be based on collaboration between 
multiple subspecialties. Patients should also continue to receive age-appropriate 
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screening as indicated for the general population with respect to conditions other 
than breast cancer.
Cancer diagnoses are also associated with increased patient distress and anxiety 
[84]. Therefore, clinicians are strongly encouraged to consider psychosocial sup-
port for long-term breast cancer survivors, as an important complement to clinical 
monitoring. Providing integrated care that is directed to the overall wellness of the 
patient, maximizes the potential to increase patient satisfaction, increase patient 
medical compliance, and preserve quality of life [85–87]. Interestingly, it has also 
been found that ethnic minority groups, who typically report poorer quality of life 
and worse distress after diagnosis, may derive more acute benefit from integrated 
modalities like art therapy [88]. It is also of importance to note that effective 
psychosocial support programs have been shown to be significantly associated with 
favorable clinical outcomes [84, 89–92].
7. Conclusions
The advancement of screening modalities and novel therapies has led to more 
favorable prognoses in patients with breast cancer. As a result, long-term breast 
cancer survivors are a large and continually-growing group, globally. This group is 
also projected to increase, substantially, within coming years. While these trends 
are favorable and clinically promising, patients with breast cancer should undergo 
regular follow-up for surveillance and management of treatment-related effects, 
as well as potential disease recurrence. In the time of the COVID-19 pandemic, 
it is also important to note a potential combinatorial effect of possible complica-
tions secondary to cancer treatment received, and possible impact on screening 
and treatment delays imposed by the novel coronavirus, on both communities and 
health care delivery systems.
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